PLC stands for different things depending on the context. In biology and medicine, it most commonly refers to either phospholipase C, a critical enzyme involved in cell signaling, or pityriasis lichenoides chronica, an uncommon inflammatory skin condition. Both meanings come up frequently in health and science settings, so here’s what you need to know about each.
PLC as an Enzyme: Phospholipase C
Phospholipase C is an enzyme found inside cells that plays a central role in how your body sends signals from one cell to another. It works by breaking apart a specific fat molecule in cell membranes called PIP2, splitting it into two smaller molecules that each trigger their own chain of events inside the cell. This single reaction is one of the most important switches in cell communication.
The first product, called DAG, stays in the cell membrane and activates a protein that controls functions like cell growth, polarity, and even learning and memory. The second product, IP3, is a small water-soluble molecule that floats through the inside of the cell until it reaches a storage compartment called the endoplasmic reticulum. There, it triggers the release of calcium ions into the cell, causing a rapid spike in calcium levels that acts as an activation signal.
That calcium spike is what makes PLC so important. Calcium is one of the body’s universal “go” signals, and through this mechanism, PLC signaling helps regulate cell growth, cell division, immune responses, hormone secretion, fertilization, sensory perception, and gene expression. Mammals have at least 11 distinct versions of the enzyme, grouped into four main families, each activated by different triggers. Some respond to signals from receptor proteins on the cell surface, others are activated by rising calcium levels themselves, and still others respond to proteins involved in cell growth regulation.
How the PLC Signaling Pathway Works
The process begins when a signaling molecule outside the cell, such as a hormone or neurotransmitter, binds to a receptor on the cell surface. Many of these receptors are G protein-coupled receptors, a large family of proteins embedded in cell membranes. When the signal binds, the receptor activates a G protein on the inside of the membrane, which in turn switches on phospholipase C.
Once activated, PLC moves to the inner surface of the cell membrane and finds its target: PIP2. It cleaves this molecule into DAG and IP3. IP3 travels to the endoplasmic reticulum and opens calcium channels there, flooding the cell’s interior with calcium. DAG, meanwhile, activates its own set of downstream proteins. Together, these two messengers amplify the original signal from outside the cell into a complex internal response. This pathway is involved in nearly every tissue type in the body, from immune cells to neurons to muscle fibers.
PLC as a Skin Condition: Pityriasis Lichenoides Chronica
In dermatology, PLC refers to pityriasis lichenoides chronica, the milder, longer-lasting form of a skin condition called pityriasis lichenoides. It causes small, raised pink or discolored spots that tend to cluster together, typically appearing on the trunk, arms, and legs. The spots are covered with a firm, shiny scale that, when scraped off by a dermatologist, reveals a red-brown or discolored surface underneath. This feature often helps confirm the diagnosis.
PLC is generally not painful. Most people experience no itching or irritation, which distinguishes it from the acute form of the condition (called PLEVA). Individual spots flatten within three to four weeks as the scale loosens, but new spots commonly appear as old ones fade, giving the condition a waxing-and-waning pattern. The average duration of pityriasis lichenoides overall is about 18 months, though some cases persist for years. Younger patients and those with more widespread spots tend to have longer courses.
How PLC Differs From PLEVA
Pityriasis lichenoides has two main forms, and they look and feel quite different. PLC develops gradually over days, produces spots that are less red or inflamed, and rarely causes symptoms beyond the visible skin changes. It can sometimes be mistaken for psoriasis because of its scaly, flaky appearance. Scarring is uncommon.
PLEVA, the acute form, often starts with feeling unwell and feverish. The rash begins as flat pink spots that quickly become inflamed, may blister, and can develop blood-stained crusting. It frequently looks like chickenpox but takes much longer to clear. PLEVA spots tend to itch, burn, or irritate as they appear. In rare cases, PLEVA can progress into a severe, life-threatening variant that involves high fever, abdominal pain, joint pain, and other systemic symptoms. PLC does not carry this risk, though in uncommon cases a very small number of PLC patients have later been found to have a type of skin lymphoma, which is why persistent or treatment-resistant cases sometimes warrant further evaluation.
What Causes PLC
The exact cause of pityriasis lichenoides chronica remains unclear. The leading theory is that it represents an inflammatory reaction in genetically susceptible individuals, triggered by an infection, particularly a virus. Studies suggest it behaves as a benign overgrowth of certain immune cells, set off by some kind of antigenic trigger. Associations have been reported with prior viral infections and, in some cases, viral vaccinations. Abnormal T-cell behavior and inflammation of small blood vessels have also been proposed as contributing mechanisms, but no single cause has been definitively established.
Treatment for PLC
Because PLC is a chronic condition that comes and goes, treatment focuses on reducing the severity and frequency of flare-ups rather than achieving a permanent cure. A systematic review of available treatments found that narrowband UVB phototherapy, a type of controlled ultraviolet light exposure, is the most effective first-line option. Sessions are typically done in a dermatology clinic over several weeks.
When phototherapy isn’t available or isn’t effective, oral antibiotics combined with topical steroid creams serve as a second-line approach. For stubborn cases, low-dose immunosuppressive medication may be considered. The spots themselves leave temporary dark marks as they heal, which gradually fade over time. Since the condition often resolves on its own within about 18 months, some patients and their dermatologists choose to monitor it rather than treat aggressively, particularly if the spots aren’t causing distress.